Subscribe to RSS - CGMs

CGMs

DMS looks beyond strips

 - 
10/28/2019

NEW ORLEANS –With the national mail-order program for diabetes testing supplies drastically changing the marketplace, provider Cynthia Pazos made a deliberate shift toward insulin pumps and other advanced diabetes therapies in 2016—and hasn’t looked back.

Ascensia partners with CGM maker

 - 
01/09/2019

BASEL, Switzerland – Ascensia Diabetes Care is partnering with Zhejiang POCTech, Co., a manufacturer of continuous glucose monitoring systems, to serve as its exclusive distributor in 13 markets.

FDA approves FreeStyle app

 - 
11/01/2018

ABBOTT PARK, Ill. – The FreeStyle LibreLink app has been approved by the U.S. Food and Drug Administration for the iPhone, according to a press release from Abbott. The app allows user to capture and view real-time glucose levels.

Abbott upgrades FreeStyle Libre

 - 
08/01/2018

ABBOTT PARK, Ill. – The U.S. Food and Drug Administration has approved Abbott’s FreeStyle Libre 14-day Flash Glucose Monitoring System.

In brief: CMS to allow use of IFR rates, ActivStyle boosts biz

 - 
06/15/2018

WASHINGTON – CMS has agreed that states can process claims using the higher fee schedule amounts for claims in rural areas from June 1-Dec. 16, 2018, according to a bulletin from AAHomecare.

CMS changes course on CGM policy

 - 
06/12/2018

WASHINGTON – CMS will allow Medicare beneficiaries to use smart phone technology with their continuous glucose monitors, it announced.

Dexcom ships G5 to Medicare beneficiaries

 - 
08/25/2017

SAN DIEGO – Dexcom has begun shipping the Dexcom G5 to Medicare beneficiaries who meet coverage requirements for continuous glucose monitoring, according to news reports. CMS in January classified “therapeutic” CGMs as DME, paving the way for coverage if certain criteria are met. In July, Dexcom reached an agreement with Ascensia Diabetes Care to bundle Ascensia’s ContourNext One glucose monitoring system with the G5. CMS has set a one-time fee of $236 to $277 for the CGM receiver, and a monthly allowable of $248.38 for related accessories. Demand for the G5 is so high that 20,000 beneficiaries are “in the pipeline” for a device. The G5 is currently the only CGM approved for insulin dosing.

CMS says CGMs cannot be used with other technology

 - 
03/30/2017

WASHINGTON – Medicare beneficiaries using Dexcom’s G5 Mobile continuous glucose monitoring system cannot use smartphone apps or tablets to display glucose data if they want to have the CGM device reimbursed, according to recently released

Diabetes in the news, in my life

 - 
Thursday, February 2, 2017

CGMs are all around me. Ads for the Dexcom G5, in particular, keep popping up on websites. I am guessing this is because I Googled it while writing a story about Medicare’s recent decision to start paying for certain CGMs (the Dexcom currently being the only one that meets the criteria at this time).

CMS approves CGMs—what now?

 - 
01/27/2017

WASHINGTON – CMS’s recent decision to classify certain continuous glucose monitoring systems as DME is a positive step, but there are a few dominoes that need to fall before they are paid for, say stakeholders.

Pages